Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business
By Mauro Orru
Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and efforts to develop cancer treatments.
The Swiss pharmaceutical company said Thursday that it would pay $1 billion up front for Watertown, Mass.-based Mariana Oncology, with an additional $750 million in payments upon completion of certain milestones.
Mariana Oncology focuses on novel radioligand therapies, or RLTs, to treat cancers. RLTs bind to specific receptors on the surface of certain types of tumors. Once bound, emissions from therapeutic radioisotopes cause DNA damage that can inhibit cell growth and replication.
Novartis currently has two approved RLTs for patients with metastatic castration-resistant prostate cancer and certain types of gastroenteropancreatic neuroendocrine tumors.
The deal is subject to customary closing conditions.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
May 02, 2024 07:36 ET (11:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now